CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel

Published:2018-08-20 Issue:2 Volume:105 Page:448-457
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Holmberg Mikko T.¹,Tornio Aleksi¹,Paile‐Hyvärinen Maria¹,Tarkiainen E. Katriina¹,Neuvonen Mikko¹,Neuvonen Pertti J.¹,Backman Janne T.¹,Niemi Mikko¹

Affiliation:

1. Department of Clinical PharmacologyUniversity of Helsinki and HUSLABHelsinki University Central HospitalHelsinkiFinland

Funder

Sigrid Juséliuksen Säätiö

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1177

Reference50 articles.

1. Genetic Determinants of Response to Clopidogrel and Cardiovascular Events

2. Greater Inhibition of Platelet Aggregation and Reduced Response Variability With Prasugrel Versus Clopidogrel: An Integrated Analysis

3. Prasugrel Overcomes High On-Clopidogrel Platelet Reactivity Post-Stenting More Effectively Than High-Dose (150-mg) Clopidogrel

4. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

5. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association;Circulation;2024-08-06

2. Genetic variation present in the CYP3A4 gene in Ni-Vanuatu and Kenyan populations in malaria endemicity;Drug Metabolism and Pharmacokinetics;2024-08

3. Pharmacogenetic considerations in therapy with novel antiplatelet and anticoagulant agents;Pharmacogenetics and Genomics;2024-02-19

4. Progress in the clinical effects and adverse reactions of ticagrelor;Thrombosis Journal;2024-01-10

5. CYP3A4*22 and bleeding risk in ticagrelor users;Basic & Clinical Pharmacology & Toxicology;2024-01-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3